⌘K

18:09:47·69d

SECFilingvia Quantisnow

Amendment: SEC Form SCHEDULE 13G/A filed by enGene Holdings Inc.

ByQuantisnow·Wall Street's wire, on your screen.

ENGN· enGene Therapeutics Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

ENGN
enGene Therapeutics Inc.
Health Care

Recent analyst ratings

Apr 13UpdateWBB Securities$21.50
Jan 30UpdateJefferies$28.00
Nov 11UpdateRaymond James$27.00
Feb 18UpdatePiper Sandler$26.00
Feb 14UpdateUBS$7.00
Dec 23UpdateH.C. Wainwright$25.00

Related

ANALYST14d
WBB Securities initiated coverage on enGene Therapeutics with a new price target
SEC18d
enGene Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
PR39d
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
SEC49d
SEC Form S-8 filed by enGene Holdings Inc.
SEC49d
SEC Form 424B5 filed by enGene Holdings Inc.
SEC49d
enGene Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement
SEC49d
SEC Form 10-Q filed by enGene Holdings Inc.
SEC49d
enGene Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits